McKesson Corporation Reports Fiscal 2025 Second Quarter Results and Raises Full Year Adjusted EPS Guidance
McKesson Corporation (NYSE: MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on ...
McKesson Corporation Reports Strong Q2 Earnings Growth
McKesson Corporation ( (MCK) ) has released its Q2 earnings. Here is a breakdown of the information McKesson Corporation presented to its ...
MCK Stock Gains as Q2 Earnings & Sales Top Estimates, '25 EPS View Up
McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical ...
kalkinemedia8h
Baird Sees McKesson Stock Poised for Upside, Driven by US Pharma...
Highlights:,Baird upgraded McKesson Corporation’s stock from Neutral to Outperform, raising its price target to $688 from $531.,McKesson's strong performance in the U.S. Pharmaceutical Distribution ...
McKesson's Fiscal Q2 EPS Tops Forecast
McKesson's earnings for its fiscal 2025 second quarter exceeded expectations, despite special charges that cut into net ...
Stock market today: Wall Street ticks higher ahead of the Fed’s decision on interest rates
U.S. stocks are ticking higher ahead of the Federal Reserve’s announcement coming later in the afternoon about what it will ...
McKesson raises annual profit forecast on strength in its U.S. pharma segment
Drug distributor McKesson Corp raised its annual profit forecast on Wednesday, driven by increased sales in its U.S.
McKesson’s Strong Q2 Performance Leads to Upward EPS Revision, But Hold Rating Due to Segment Concerns and Uncertain Long-Term Growth
Steve Baxter, an analyst from Wells Fargo, maintained the Hold rating on McKesson (MCK – Research Report). The associated price target ...
McKesson upgraded at Baird on Core Ventures deal after Q2 beat
McKesson (MCK) stock traded higher as Baird upgraded the company to outperform citing its Core Ventures deal and its strong Q2 FY25 earnings. Read more here.
These Analysts Boost Their Forecasts On McKesson Following Upbeat Earnings
McKesson MCK reported better-than-expected second-quarter financial results on Wednesday. McKesson reported quarterly earnings of $7.07 per share which beat the analyst consensus estimate of $6.88 per ...
What you need to know in Baltimore’s opioid case before it heads to jurors
Fletcher-Hill sends the case to the jury for consideration. Baltimore alleges that the companies, McKesson and AmerisourceBergen, flooded the city with hundreds of millions of addictive pain pills ...